Dr. O'Shaughnessy on Adding Phosphoprotein Testing to Genomic Testing for Breast Cancer

Joyce A. OShaughnessy, MD
Published: Thursday, Aug 13, 2015



Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses adding phosphoprotein testing to genomic testing for patients with breast cancer.

O’Shaughnessy explains she has often used phosphoprotein analyses in order to determine driving mutations in refractory tumors. For example, she mentions a patient with refractory triple-negative breast cancer who, upon genomic analysis, had several mutational abnormalities. Therefore, a clear treatment plan could not be determined. However, by using a phosphoprotein assay, fibroglast growth factor receptor was found to be the single driving mutation.

This is helpful, O’Shaughnessy says, because several mutational abnormalities may act as passengers and/or are inactive in patients, and the driving mutation may not be determined solely with a genomic analysis.
 
SELECTED
LANGUAGE


Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses adding phosphoprotein testing to genomic testing for patients with breast cancer.

O’Shaughnessy explains she has often used phosphoprotein analyses in order to determine driving mutations in refractory tumors. For example, she mentions a patient with refractory triple-negative breast cancer who, upon genomic analysis, had several mutational abnormalities. Therefore, a clear treatment plan could not be determined. However, by using a phosphoprotein assay, fibroglast growth factor receptor was found to be the single driving mutation.

This is helpful, O’Shaughnessy says, because several mutational abnormalities may act as passengers and/or are inactive in patients, and the driving mutation may not be determined solely with a genomic analysis.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Publication Bottom Border
Border Publication
x